Drug intelligence / Profile preview

si-WTAP

Development stage: Preclinical
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Typically Intracellular Delivery Via Transfection

Overview

si-WTAP is a small interfering RNA (siRNA) designed to target and silence the expression of the WTAP gene. WTAP is involved in the regulation of N6-methyladenosine (m6A) modification in RNA, which plays roles in various cellular processes, including tumor progression and adaptation to hypoxia.

Other names: siRNA targeting WTAP

Targets

WTAP (Pre-mRNA-splicing regulator WTAP)

Beyond the preview

Go deeper on si-WTAP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on si-WTAP.

Explore the full profile